MPG.eBooks - Description: Selexipag (Uptravi)

Cover Image

Read Now

Selexipag (Uptravi)

The objective of this systematic review is to evaluate the beneficial and harmful effects of selexipag tablets for the treatment of pulmonary arterial hypertension (PAH) in adults (World Health Organization [WHO] FC II or III)

Bibliographic Details
Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health September 2017, 2017
Series:	CADTH common drug review clinical review report
Subjects:	Acetamides / Adverse Effects Canada Antihypertensive Agents Acetamides / Therapeutic Use Hypertension, Pulmonary / Drug Therapy Pyrazines / Adverse Effects Pyrazines / Therapeutic Use
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK533864
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The objective of this systematic review is to evaluate the beneficial and harmful effects of selexipag tablets for the treatment of pulmonary arterial hypertension (PAH) in adults (World Health Organization [WHO] FC II or III)
Physical Description:	1 PDF file (53 pages) illustrations